Global Glioblastoma Multiforme Industry to 2030

DUBLIN, February 7, 2022 /PRNewswire/ — The “Glioblastoma Multiforme – Global Drug Forecast and Market Analysis to 2030” report has been added to from offer.

Glioblastoma multiforme (GBM) is now defined by WHO 2021 as diffuse astrocytic glioma without mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in men. Like other astrocytomas, GBM arises from astrocytes, a type of glial cell that is non-neuronal and functions to provide structural and biochemical support to the brain’s neural network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is mainly due to the inability of drugs to penetrate the blood-brain barrier (BBB).

The GBM market is mainly based on temozolomide and bevacizumab, which accounted for 46% and 51% of the total, respectively. $549.1 million sales in 2020. For this market to experience true growth, currently marketed products are expected to be almost entirely replaced by new products in the pipeline, due to the large presence of generic temozolomide and the introduction of bevacizumab biosimilars. However, a high failure rate has historically been observed for late-stage GBM trials and may impact pipeline forecasts and hamper market growth. Nevertheless, eight pipeline agents are expected to enter the 8MM and drive GBM’s growth to $868.5 million by 2030 at a compound annual growth rate (CAGR) of 4.7%.


  • Key growth drivers include the planned approval and launch of eight pipeline agents over the forecast period, of which cancer vaccines and protein kinase inhibitors are the dominant classes.
  • The primary impediment to growth over the forecast period will be the historically high failure rates seen for GBM Phase III trials, which will impact pipeline forecasts. The high genericity of temozolomide and the recent patent expiration of Avastin, leading to biosimilar entry, also reduce the market potential for glioblastoma multiforme (GBM).
  • DCVax-L, regorafenib and paxalisib are the three pipeline agents expected to generate the highest sales for GBM from 2020 to 2030.
  • Besides OS improvement, other key unmet needs in the GBM market include; Predictive biomarkers to guide personalized treatment and the need to find more effective therapy in O6-methylguanine-DNA methyltransferase (MGMT) unmethylated patients who typically have a poor response to temozolomide.

Answers to key questions

  • Eight agents in the phase II-III pipeline are expected to enter the glioblastoma market starting in 2024. What impact will these agents have on the market?
  • Which of these drugs will have the highest spike in sales, and why?
  • What are the current unmet needs in GBM, which agents in the pipeline are positioned to meet these unmet needs?
  • What opportunities for R&D?
  • What research and development (R&D) strategies are currently being explored and how can developers incorporate these methods into their business strategy?
  • What is the expected future uptake of protein kinase inhibitors in 8MM?


  • Overview of glioblastoma multiforme, including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Glioblastoma Multiforme Market revenue, annual therapy cost and major pipeline product sales during the forecast period.
  • Key topics covered include current treatments and on-going therapies, unmet needs and opportunities, and drivers and barriers affecting sales of glioblastoma multiforme therapeutics in 8MM.
  • Pipeline Analysis: Comprehensive data split across different phases, new emerging trends under development, and detailed analysis of late-stage (Phase II – III) pipeline drugs.
  • Analysis of the current and future competition in the global glioblastoma multiforme therapeutics market. In-depth look at key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to buy
The report will allow you to:

  • Develop and design your licensing and licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Glioblastoma Multiforme Therapeutics market.
  • Generate revenue by understanding the key trends, innovative products and technologies, market segments, and companies that are likely to impact the global glioblastoma multiforme market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Track global glioblastoma multiforme therapeutics market drug sales from 2020 to 2030.
  • Organize your sales and marketing efforts by identifying the categories and market segments that present the maximum opportunities for consolidations, investments and strategic partnerships.

Main topics covered:

1 Glioblastoma Multiforme: Executive Summary
1.1 Glioblastoma Multiforme Market is Expected to Reach $868.5 million by 2030 on 8MM
1.2 GBM-AGILE candidates poised to enter market as Merck & Co. expands early-stage portfolio and Roche suffers erosion
1.3 High Unmet Need Exists in the GBM Market, Particularly Among MGMT-Promoting Unmethylated Patients and Unresectable Patients
1.4 Opportunities for new entrants with better prognostic markers and drug targets
1.5 GBM-AGILE New Drug Candidates and Immunotherapies Expected to Launch During the Forecast Period
1.6 What do doctors think?

2 Presentation
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming reports

3 Overview of the disease
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or grading systems

4 Epidemiology
4.1 Context of the disease
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 8MM Forecast Methodology
4.4.1 Origin
4.4.2 Assumptions and forecasting methods
4.4.3 Diagnosed Incident Cases of Brain cancer
4.4.4 Diagnosed Incident Cases of Brain cancer by type
4.4.5 Diagnosed incident cases of glioblastoma by grade
4.4.6 Diagnosed incident cases of glioblastoma by origin
4.4.7 Incident cases diagnosed with glioblastoma by biomarkers
4.4.8 Diagnosed incident cases of glioblastoma by mutations
4.4.9 Prevalent cases diagnosed over five years of Brain cancer
4.5 Debate
4.5.1 Overview of epidemiological forecasts
4.5.2 Impact of COVID-19
4.6 Epidemiological forecasts for Brain cancer (2020-2030)
4.6.1 Diagnosed Incident Cases of Brain cancer
4.6.2 Diagnosed Incident Cases by Age Brain cancer
4.6.3 Diagnosed Incident Cases by Gender Brain cancer
4.6.4 Diagnosed Incident Cases of Brain cancer by type
4.6.5 Diagnosed incident cases of glioblastoma by grade
4.6.6 Diagnosed incident cases of glioblastoma by origin
4.6.7 Incident cases diagnosed with glioblastoma by biomarkers
4.6.8 Diagnosed incident cases of glioblastoma by mutations
4.6.9 Prevalent cases diagnosed over five years of Brain cancer
4.6.10 Analysis limits
4.6.11 Analysis Highlights

5 Disease management
5.1 Overview of diagnosis and treatment
5.2 KOL perspectives on disease management

6 current treatment options
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Identification and validation of biomarkers and drug targets
7.3 Overcoming the blood-brain barrier to improve treatment efficacy
7.4 Best Treatment Options for Unmethylated and Unresectable MGMT Patients
7.5 Differentiating between pseudo-progression and true progression

9 R&D Strategies
9.1 Overview
9.1.1 Efficacy of immunotherapy in GBM
9.1.2 Predictive biomarkers and targeted therapy
9.1.3 Improving therapy delivery routes
9.2 Design of clinical trials
9.2.1 Clinical parameters
9.2.2 More Umbrella or Platform Trial Designs
9.2.3 Indicator arm

10 Pipeline Assessment
10.1 Overview
10.2 Promising drugs in clinical development

11 Pipeline Assessment Analysis
11.1 Overview
11.2 Competitive Evaluation

12 current and future players
12.1 Overview
12.2 Transaction Trends

13 Market Outlook

14 Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets

Comments are closed.